Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer
Open accessThe DOI matches its Crossref record; 286 of the 286 references it cites were found in a registry or an index; 27 of the 131 sources its claims cite were checked for support.
Abstract
Guideline article describing standard treatment strategies for colorectal cancer and summarizing evidence-based recommendations.
Overview
CoChat Summary
TL;DR
The JSCCR Guidelines 2016 present consensus-based standard treatment strategies for colorectal cancer in Japan, covering endoscopic and surgical treatment, chemotherapy, radiotherapy, palliative care, and surveillance. They use literature review, GRADE-style evidence assessment, and Delphi consensus to issue recommendations for clinical questions.
Key findings
- Colorectal cancer mortality in Japan surpassed 49,000 in 2015, and deaths per unit population increased approximately tenfold over the past 50 years.
- After curative resection of pStage 0–III colorectal cancer, 5-year survival rates by site were: all sites 82.2%, colon 83.8%, rectosigmoid 81.7%, and Ra–Rb rectum 79.3% (patients treated 2000–2004).
- For rectal cancer with the lower tumor border distal to the peritoneal reflection and invasion beyond the muscularis propria, lateral lymph node metastasis rate was 20.1%; lateral lymph node dissection was expected to reduce intrapelvic recurrence risk by 50% and improve 5-year survival by 8–9%.
- For pT1 (SM) colorectal cancer, the lymph node metastasis rate was 12.5% when submucosal invasion depth was ≥1000 μm; Stage II postoperative adjuvant chemotherapy was not recommended routinely (recommendation/evidence level 1A), while 6 months was the standard duration for 5-FU-based adjuvant chemotherapy (1A).
Methods
- These guidelines were prepared by the JSCCR Guideline Committee by consensus, based on literature searches and consideration of the Japanese health insurance system and clinical practice.
- Literature searches used PubMed and Ichushi-Web from January 2008 to March 2012, with the search period extended to July 2016 for adjuvant chemotherapy and chemotherapy for advanced or recurrent colorectal cancer; 12,000 documents were retrieved (PubMed 7909, Ichushi 4091), and 2320 were selected and critically reviewed.
- Evidence levels and strength of recommendations were assessed with reference to the GRADE system; recommendation strength was determined by Delphi-method voting, with ≥70% committee consensus required.
Limitations
- Stated: the guidelines provide only general recommendations and do not control or limit treatment strategies or methods not described; responsibility for treatment outcomes rests with the personnel directly in charge, not the JSCCR or Guideline Committee.
- Stated: no strength of recommendation was presented in clinical questions, and for several interventions the efficacy and safety were not established, with calls for appropriately planned clinical trials.
- Evident from the text: recommendations are explicitly framed around the Japanese medical insurance system and actual clinical practice in Japan, and the literature search periods ended in 2012 or 2016, so applicability outside Japan or to later evidence is limited.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures















Verification
Claims the paper makes
14 Valid · 15 Not valid · 52 Not checked · 49 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Randomized controlled trials involving PS 0 to PS 2 patients have shown that chemotherapy groups have a significantly longer survival time than BSC groups that did not receive anticancer drugs [54–56].”
§ Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer > Abstract
What the sources say
- Partly supportedcites [54] Scheithauer W Rosen H Kornek GV Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer BMJ 1993 306 752 755 10.1136/bmj.306.6880.752 7683942 PMC1677246 sourceExperimental — accuracy not yet measured
The Results report significantly longer survival in the chemotherapy arm than in the supportive-care arm (median 11 versus 5 months; p=0.006). However, Table I groups some participants as PS 2–3, so this trial cannot establish that all participants had PS 0–2. The Results also state that two participants assigned to supportive care later received an anticancer drug. (LLM, conf=0.88)
- Partly supportedcites [55] Simmonds PC Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. Colorectal Cancer Collaborative Group BMJ 2000 321 531 535 10.1136/bmj.321.7260.531 10968812 PMC27466 sourceExperimental — accuracy not yet measured
The Survival section reports significantly longer survival for the chemotherapy group in a pooled analysis of randomized trials. However, the paper does not establish that the patients were restricted to PS 0–2, and the Description of studies and Discussion note that some supportive-care patients subsequently received chemotherapy. The claim’s absolute description of the control groups is therefore not supported. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [56] Cunningham D Pyrhonen S James RD Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer Lancet 1998 352 1413 1418 10.1016/S0140-6736(98)02309-5 9807987 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“There are reports showing the efficacy of hepatectomy in patients who have controllable extrahepatic metastases (mainly lung metastases) in addition to liver metastases [35, 36, 39, 43] (CQ-7).”
§ Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer > Abstract
What the sources say
- Not checked — no full text of the sourcecites [35] Murata S Moriya Y Akasu T Resection of both hepatic and pulmonary metastases in patients with colorectal carcinoma Cancer 1998 83 1086 1093 10.1002/(SICI)1097-0142(19980915)83:6<1086::AID-CNCR6>3.0.CO;2-6 9740072 doi:10.1002/(sici)1097-0142(19980915)83:6
- Supportedcites [36] Kobayashi K Kawamura M Ishihara T Surgical treatment for both pulmonary and hepatic metastases from colorectal cancer J Thorac Cardiovasc Surg 1999 118 1090 1096 10.1016/S0022-5223(99)70106-6 10595983 source
The Discussion says that synchronous pulmonary metastases should not necessarily be considered a poor prognostic factor for hepatectomy. The paper reports 31% five-year survival after both pulmonary and hepatic resection and concludes that surgery may be appropriate when the metastases are resectable, particularly with a solitary pulmonary metastasis. (LLM, conf=0.90)
- Supportedcites [39] Robinson BJ, Rice TW, Strong SA et al (1999) Is resection of pulmonary and hepatic metastases warranted in patients with colorectal cancer? J Thorac Cardiovasc Surg 117:66–75 (discussion 75–76) 9869759 source
The Conclusions report improved survival after resection of both liver and lung metastases in selected patients with colorectal cancer. This supports the citing sentence’s characterization of the paper as a report of benefit from hepatectomy when lung metastases are also amenable to resection; the finding is limited to selected patients, particularly those with metachronous solitary metastases. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [43] Regnard JF, Grunenwald D, Spaggiari L et al (1998) Surgical treatment of hepatic and pulmonary metastases from colorectal cancers. Ann Thorac Surg 66:214–8 (discussion 218–219) 9692467 source
- Not matchedcites CQ-7
This doesn’t read as a citation we can look up.
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The incidences of sexual dysfunction and bowel dysfunction were higher in the preoperative radiation combination therapy group than in the surgery-alone group [113, 114].”
§ Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer > Abstract
What the sources say
- Not checked — no full text of the sourcecites [113] Marijnen CA van de Velde CJ Putter H Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial J Clin Oncol 2005 23 1847 1858 10.1200/JCO.2005.05.256 15774778 source
- Supportedcites [114] Peeters KC van de Velde CJ Leer JW Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients–a Dutch colorectal cancer group study J Clin Oncol 2005 23 6199 6206 10.1200/JCO.2005.14.779 16135487 source
The Patients section reports more bowel dysfunction after preoperative radiotherapy plus surgery than after surgery alone. The Discussion also reports significantly more sexual dysfunction in irradiated patients, citing a concomitant study by the same group. Page numbers are not available in our copy. (LLM, conf=0.90)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“OX increased harmful phenomena in three tests”
§ Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer > Abstract
What the sources say
- Not checked — no full text of the sourcecites [120] Hofheinz RD Wenz F Post S Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial Lancet Oncol 2012 13 579 588 10.1016/S1470-2045(12)70116-X 22503032 source
- Partly supportedcites [122] Aschele C Cionini L Lonardi S Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial J Clin Oncol 2011 29 2773 2780 10.1200/JCO.2010.34.4911 21606427 sourceExperimental — accuracy not yet measured
The Compliance and Acute Toxicity section reports more grade 3–4 adverse events when oxaliplatin was added to preoperative fluorouracil and radiotherapy (24% versus 8%). The Discussion says increased acute toxicity was seen in two randomized phase III trials, not three; the claimed number of tests is unsupported. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [123] Gerard JP Azria D Gourgou-Bourgade S Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12/0405-Prodige 2 J Clin Oncol 2010 28 1638 1644 10.1200/JCO.2009.25.8376 20194850 source
- Supportedcites [124] Gérard JPAD Gourgou-Bourgade S Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer J Clin Oncol 2012 30 4558 4565 10.1200/JCO.2012.42.8771 23109696 sourceExperimental — accuracy not yet measured
The Discussion reports increased grade 3–4 acute toxicity with oxaliplatin in the ACCORD 12, STAR-01, and NSABP R04 randomized trials. It also notes that the CAO/ARO 04 trial did not show an overall toxicity increase, although one subgroup did. The claim is supported when “harmful phenomena” refers to acute toxicity. (LLM, conf=0.88)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The incidence of acute-phase adverse events was significantly higher in the preoperative chemoradiotherapy groups”
§ Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer > Abstract
What the sources say
- Not checked — no full text of the sourcecites [111] Peeters KC Marijnen CA Nagtegaal ID The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma Ann Surg 2007 246 693 701 10.1097/01.sla.0000257358.56863.ce 17968156 source
- Not checked — no full text of the sourcecites [112] van Gijn W Marijnen CA Nagtegaal ID Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial Lancet Oncol 2011 12 575 582 10.1016/S1470-2045(11)70097-3 21596621 source
- Not checked — no full text of the sourcecites [113] Marijnen CA van de Velde CJ Putter H Impact of short-term preoperative radiotherapy on health-related quality of life and sexual functioning in primary rectal cancer: report of a multicenter randomized trial J Clin Oncol 2005 23 1847 1858 10.1200/JCO.2005.05.256 15774778 source
- Could not verifycites [114] Peeters KC van de Velde CJ Leer JW Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients–a Dutch colorectal cancer group study J Clin Oncol 2005 23 6199 6206 10.1200/JCO.2005.14.779 16135487 sourceExperimental — accuracy not yet measured
The Introduction and Discussion (page unavailable) discuss acute toxicity after preoperative radiotherapy, but the study compares radiotherapy plus surgery with surgery alone and focuses on late side effects. A search for chemoradiotherapy and acute adverse events found no comparison of preoperative chemoradiotherapy with radiotherapy alone in our copy. (LLM, conf=0.76)
- Not checked — no full text of the sourcecites [115] Francois Y Nemoz CJ Baulieux J Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial J Clin Oncol 1999 17 2396 10.1200/JCO.1999.17.8.2396 10561302 source
- Supportedcites [116] Bosset JF Collette L Calais G Chemotherapy with preoperative radiotherapy in rectal cancer N Engl J Med 2006 355 1114 1123 10.1056/NEJMoa060829 16971718 source
The Preoperative treatment section reports higher rates of grade 2 and grade 3-or-higher acute toxic effects with preoperative chemoradiotherapy than with radiotherapy alone, with a significant difference (P for trend <0.001). The Discussion likewise says that adding chemotherapy increased acute toxic effects. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites [117] Bujko K Nowacki MP Nasierowska-Guttmejer A Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer Br J Surg 2006 93 1215 1223 10.1002/bjs.5506 16983741 source
- Not checked — no full text of the sourcecites [118] Gerard JP Conroy T Bonnetain F Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203 J Clin Oncol 2006 24 4620 4625 10.1200/JCO.2006.06.7629 17008704 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
81 more claims · 9 with their cited sources checked
Create a free account to see all 130 claims and to verify the 1 reference still open.
- It may state two separate claims as one. 25
- Probably not a substantial claim. 21
- The quote only partly states this claim. 3
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer > Abstract
“No strength of recommendation was presented in CQs.”
§ Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer > Abstract
“Surgical resection is preferable when the vertical margin is positive (recommendation/evidence level 1C).”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer > Abstract
“If the distant metastases are unresectable, but the primary tumor is resectable, the indication for the resection of the primary tumor is determined, based on the clinical symptoms of the primary tumor and the impact on the prognosis (CQ-4).”
§ Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer > Abstract
“CQ-5: resection of the primary tumor in patients with unresectable distant metastases”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer > Abstract
““JSCCR Guidelines 2016 for the Clinical Practice of Hereditary Colorectal Cancer.” [105].”
§ Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer > References
“105. Japanese Society for Cancer of the Colon and Rectum (2016) JSCCR guidelines 2012 for the clinical practice of hereditary colorectal cancer.”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer > Abstract
“no randomized controlled trials have been implemented regarding whether or not it extends survival [37, 38].”
§ Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer > References
“37. Portier G Elias D Bouche O Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial”
Citations
Cites
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Cancer: Principles and Practice of Oncology.
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-9-819_4 · Cited by 8,516
GRADE guidelines: 3. Rating the quality of evidence
Balshem, H., Helfand, M., Schünemann, H. J., Oxman, A. D., Kunz, R., Brozek, J., Vist, G. E., Falck-Ytter, Y., Meerpohl, J., & Norris, S. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.015 · Cited by 8,285 · cited 1×
“(CQ-1) Table 2 Definition of levels of evidence (Reference [13])”
BackgroundPreoperative versus Postoperative Chemoradiotherapy for Rectal Cancer
Sauer, R., Becker, H., Hohenberger, W., Rödel, C., Wittekind, C., Fietkau, R., Martus, P., Tschmelitsch, J., Hager, E., Hess, C. F., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040694 · Cited by 6,050 · cited 1×
“1 3 cantly higher in the preoperative chemoradiotherapy group [119].”
BackgroundCunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · cited 5×
“Patients not appropriate for intensive therapy • BSC • If possible, consider the optimal regimen Third-line and subsequent therapies • The following regimens should be considered for their-line and subsequent therapies • IRI + Cmab/Pmab [93] • Cmab/Pmab [94–97] • Regorafenib [98] ▪ TAS-102 [99, 100].”
BackgroundInfluentialPreoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer
Kapiteijn, E., Marijnen, C. A. M., Nagtegaal, I. D., Putter, H., Steup, W. H., Wiggers, T., Rutten, H. J. T., Pahlman, L., Glimelius, B., van Krieken, J. H. J. M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010580 · Cited by 4,205 · cited 6×
“• In the USA and Europe, although preoperative chemoradiotherapy has lowered local recurrence rates in comparison with TME-only, reports suggest that it has not contributed to improved survival rates.”
BackgroundInfluentialCetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877 · cited 4×
“(1) Patients appropriate for intensive therapy (a) When the patient has become refractory or intolerant to the first-line therapy, including OX • FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89] (b) When the patient has become refracto…”
Influentialde Gramont, A., Figer, A., Seymour, M., Homerin, M., Hmissi, A., Cassidy, J., Boni, C., Cortes-Funes, H., Cervantes, A., Freyer, G., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.2938 · Cited by 3,815 · cited 1×
“• FOLFOX (note 1) [57, 58] + Bmab [54] • CapeOX (note 2) + Bmab [59, 60] ▪ SOX + Bmab (note 3) [61] • FOLFIRI (note 4) [62, 63] + Bmab [64, 65] • FOLFOX + Cmab/Pmab [66, 67] • FOLFIRI + Cmab/Pmab [68, 69] • FOLFOXIRI (note 5) [70] ▪ FOLFOXIRI + Bmab [71, 72] • Infusional 5-FU + LV [73, 74] + Bmab [75, 76] • Cape [77,…”
Oxaliplatin, Fluorouracil, and Leucovorin as Adjuvant Treatment for Colon Cancer
André, T., Boni, C., Mounedji-Boudiaf, L., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Zaninelli, M., Clingan, P., Bridgewater, J., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032709 · Cited by 3,689
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622 · cited 2×
“• The usefulness of anti-EGFR antibody drugs has been reported in metastatic colorectal cancer without KRAS gene mutations [38–41, 47, 53, 55, 85–90].”
BackgroundNorderyd, O. M., Koch, G., Papias, A., Köhler, A. A., Helkimo, A. N., Brahm, C., Lindmark, U., Lindfors, N., Mattsson, A., Rolander, B., et al. (2015) · PubMed · Cited by 3,584
Douillard, J., Cunningham, D., Roth, A., Navarro, M., James, R., Karasek, P., Jandik, P., Iveson, T., Carmichael, J., Alakl, M., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02034-1 · Cited by 3,256 · cited 1×
“• FOLFOX (note 1) [57, 58] + Bmab [54] • CapeOX (note 2) + Bmab [59, 60] ▪ SOX + Bmab (note 3) [61] • FOLFIRI (note 4) [62, 63] + Bmab [64, 65] • FOLFOX + Cmab/Pmab [66, 67] • FOLFIRI + Cmab/Pmab [68, 69] • FOLFOXIRI (note 5) [70] ▪ FOLFOXIRI + Bmab [71, 72] • Infusional 5-FU + LV [73, 74] + Bmab [75, 76] • Cape [77,…”
What is ‘quality of evidence’ and why is it important to clinicians?
Guyatt, G. H., Oxman, A. D., Kunz, R., Vist, G. E., Falck-Ytter, Y., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39490.551019.be · Cited by 3,250
Wild-Type KRAS Is Required for Panitumumab Efficacy in Patients With Metastatic Colorectal Cancer
Amado, R. G., Wolf, M., Peeters, M., Van Cutsem, E., Siena, S., Freeman, D. J., Juan, T., Sikorski, R., Suggs, S., Radinsky, R., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7116 · Cited by 3,207 · cited 2×
“• The usefulness of anti-EGFR antibody drugs has been reported in metastatic colorectal cancer without KRAS gene mutations [38–41, 47, 53, 55, 85–90].”
BackgroundA Randomized Trial of Surgery in the Treatment of Single Metastases to the Brain
Patchell, R. A., Tibbs, P. A., Walsh, J. W., Dempsey, R. J., Maruyama, Y., Kryscio, R. J., Markesbery, W. R., Macdonald, J. S., & Young, B. (1990) · New England Journal of Medicine · doi:10.1056/nejm199002223220802 · Cited by 3,135 · cited 1×
“Indications criteria for brain resection [49]”
Saltz, L. B., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9930 · Cited by 2,955
The mesorectum in rectal cancer surgery—the clue to pelvic recurrence?
Heald, R. J., Husband, E. M., & Ryall, R. D. H. (1982) · Journal of British Surgery · doi:10.1002/bjs.1800691019 · Cited by 2,917 · cited 1×
“• Lateral lymph node dissection is indicated when the lower border of the tumor is located distal to the peritoneal reflection and the tumor has invaded beyond the muscularis propria [30].”
BackgroundTournigand, C., André, T., Achille, E., Lledo, G., Flesh, M., Mery-Mignard, D., Quinaux, E., Couteau, C., Buyse, M., Ganem, G., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.113 · Cited by 2,915
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895 · cited 5×
“Patients not appropriate for intensive therapy • BSC • If possible, consider the optimal regimen Third-line and subsequent therapies • The following regimens should be considered for their-line and subsequent therapies • IRI + Cmab/Pmab [93] • Cmab/Pmab [94–97] • Regorafenib [98] ▪ TAS-102 [99, 100].”
BackgroundInfluentialSelf-citationGRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias)
Guyatt, G. H., Oxman, A. D., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., Montori, V., Akl, E. A., Djulbegovic, B., & Falck-Ytter, Y. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.07.017 · Cited by 2,798
GRADE guidelines 6. Rating the quality of evidence—imprecision
Guyatt, G. H., Oxman, A. D., Kunz, R., Brozek, J., Alonso-Coello, P., Rind, D., Devereaux, P. J., Montori, V. M., Freyschuss, B., Vist, G., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.01.012 · Cited by 2,693
Chemotherapy with Preoperative Radiotherapy in Rectal Cancer
Bosset, J.-F., Collette, L., Calais, G., Mineur, L., Maingon, P., Radosevic-Jelic, L., Daban, A., Bardet, E., Beny, A., & Ollier, J.-C. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa060829 · Cited by 2,688
Gaspar, L., Scott, C., Rotman, M., Asbell, S., Phillips, T., Wasserman, T., McKenna, W. G., & Byhardt, R. (1997) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(96)00619-0 · Cited by 2,544
Improved Survival with Preoperative Radiotherapy in Resectable Rectal Cancer
(1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361402 · Cited by 2,517
Andrews, D. W., Scott, C. B., Sperduto, P. W., Flanders, A. E., Gaspar, L. E., Schell, M. C., Werner-Wasik, M., Demas, W., Ryu, J., Bahary, J.-P., et al. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16250-8 · Cited by 2,417
GRADE guidelines: 7. Rating the quality of evidence—inconsistency
Guyatt, G. H., Oxman, A. D., Kunz, R., Woodcock, J., Brozek, J., Helfand, M., Alonso-Coello, P., Glasziou, P., Jaeschke, R., Akl, E. A., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.03.017 · Cited by 2,320
Giantonio, B. J., Catalano, P. J., Meropol, N. J., O'Dwyer, P. J., Mitchell, E. P., Alberts, S. R., Schwartz, M. A., & Benson, A. B. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.6305 · Cited by 2,279 · cited 6×
“• FOLFOX [62, 90] + Bmab [85, 91] • CapeOX (note 2) [92] + Bmab [85] ▪ SOX + Bmab ▪ FOLFOX + Cmab/Bmab”
InfluentialAndré, T., Boni, C., Navarro, M., Tabernero, J., Hickish, T., Topham, C., Bonetti, A., Clingan, P., Bridgewater, J., Rivera, F., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.6771 · Cited by 2,277 · cited 1×
“• Randomized controlled trials conducted in Europe and the United States have shown that the combination of intravenous infusion of 5-FU ? LV and L-OHP (FOLFOX4 and FLOX) used as postoperative adjuvant chemotherapy for stage III colon cancer provides an additional benefit in terms of prevention of recurrence and survi…”
BackgroundGoldberg, R. M., Sargent, D. J., Morton, R. F., Fuchs, C. S., Ramanathan, R. K., Williamson, S. K., Findlay, B. P., Pitot, H. C., & Alberts, S. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.046 · Cited by 2,249 · cited 1×
“• FOLFOX (note 1) [57, 58] + Bmab [54] • CapeOX (note 2) + Bmab [59, 60] ▪ SOX + Bmab (note 3) [61] • FOLFIRI (note 4) [62, 63] + Bmab [64, 65] • FOLFOX + Cmab/Pmab [66, 67] • FOLFIRI + Cmab/Pmab [68, 69] • FOLFOXIRI (note 5) [70] ▪ FOLFOXIRI + Bmab [71, 72] • Infusional 5-FU + LV [73, 74] + Bmab [75, 76] • Cape [77,…”
KRAS Mutation Status Is Predictive of Response to Cetuximab Therapy in Colorectal Cancer
Lièvre, A., Bachet, J.-B., Le Corre, D., Boige, V., Landi, B., Emile, J.-F., Côté, J.-F., Tomasic, G., Penna, C., Ducreux, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0191 · Cited by 2,229 · cited 1×
“• The usefulness of anti-EGFR antibody drugs has been reported in metastatic colorectal cancer without KRAS gene mutations [38–41, 47, 53, 55, 85–90].”
BackgroundAoyama, H., Shirato, H., Tago, M., Nakagawa, K., Toyoda, T., Hatano, K., Kenjyo, M., Oya, N., Hirota, S., Shioura, H., et al. (2006) · JAMA · doi:10.1001/jama.295.21.2483 · Cited by 2,213
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979
GRADE guidelines: 2. Framing the question and deciding on important outcomes
Guyatt, G. H., Oxman, A. D., Kunz, R., Atkins, D., Brozek, J., Vist, G., Alderson, P., Glasziou, P., Falck-Ytter, Y., & Schünemann, H. J. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.09.012 · Cited by 1,911
Cetuximab for the Treatment of Colorectal Cancer
Jonker, D. J., O'Callaghan, C. J., Karapetis, C. S., Zalcberg, J. R., Tu, D., Au, H.-J., Berry, S. R., Krahn, M., Price, T., Simes, R. J., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071834 · Cited by 1,904
van Gijn, W., Marijnen, C. A., Nagtegaal, I. D., Kranenbarg, E. M.-K., Putter, H., Wiggers, T., Rutten, H. J., Påhlman, L., Glimelius, B., & van de Velde, C. J. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70097-3 · Cited by 1,888
GRADE guidelines: 8. Rating the quality of evidence—indirectness
Guyatt, G. H., Oxman, A. D., Kunz, R., Woodcock, J., Brozek, J., Helfand, M., Alonso-Coello, P., Falck-Ytter, Y., Jaeschke, R., Vist, G., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.04.014 · Cited by 1,843
GRADE guidelines: 5. Rating the quality of evidence—publication bias
Guyatt, G. H., Oxman, A. D., Montori, V., Vist, G., Kunz, R., Brozek, J., Alonso-Coello, P., Djulbegovic, B., Atkins, D., Falck-Ytter, Y., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.01.011 · Cited by 1,819
Going from evidence to recommendations
Guyatt, G. H., Oxman, A. D., Kunz, R., Falck-Ytter, Y., Vist, G. E., Liberati, A., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39493.646875.ae · Cited by 1,810
Douillard, J.-Y., Siena, S., Cassidy, J., Tabernero, J., Burkes, R., Barugel, M., Humblet, Y., Bodoky, G., Cunningham, D., Jassem, J., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.4860 · Cited by 1,809 · cited 4×
“(1) Patients appropriate for intensive therapy (a) When the patient has become refractory or intolerant to the first-line therapy, including OX • FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89] (b) When the patient has become refracto…”
InfluentialGrading quality of evidence and strength of recommendations for diagnostic tests and strategies
Schünemann, H. J., Oxman, A. D., Brozek, J., Glasziou, P., Jaeschke, R., Vist, G. E., Williams, J. W., Kunz, R., Craig, J., Montori, V. M., et al. (2008) · BMJ · doi:10.1136/bmj.39500.677199.ae · Cited by 1,782
Mesorectal excision for rectal cancer
MacFarlane, J. K., Ryall, R. D. H., & Heald, R. J. (1993) · The Lancet · doi:10.1016/0140-6736(93)90207-w · Cited by 1,781
Abdalla, E. K., Vauthey, J.-N., Ellis, L. M., Ellis, V., Pollock, R., Broglio, K. R., Hess, K., & Curley, S. A. (2004) · Annals of Surgery · doi:10.1097/01.sla.0000128305.90650.71 · Cited by 1,750
Gérard, J.-P., Conroy, T., Bonnetain, F., Bouché, O., Chapet, O., Closon-Dejardin, M.-T., Untereiner, M., Leduc, B., Francois, É., Maurel, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7629 · Cited by 1,731
Kabbinavar, F., Hurwitz, H. I., Fehrenbacher, L., Meropol, N. J., Novotny, W. F., Lieberman, G., Griffing, S., & Bergsland, E. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.066 · Cited by 1,716 · cited 7×
“(1) Patients appropriate for intensive therapy (a) When the patient has become refractory or intolerant to the first-line therapy, including OX • FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89] (b) When the patient has become refracto…”
InfluentialBokemeyer, C., Bondarenko, I., Makhson, A., Hartmann, J. T., Aparicio, J., de Braud, F., Donea, S., Ludwig, H., Schuch, G., Stroh, C., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.8397 · Cited by 1,636 · cited 4×
“(1) Patients appropriate for intensive therapy (a) When the patient has become refractory or intolerant to the first-line therapy, including OX • FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89] (b) When the patient has become refracto…”
InfluentialCetuximab in the treatment of colorectal cancer.
Goldberg, R. M., Venook, A. P., & Schilsky, R. L. (2004) · PubMed · Cited by 1,518
Schmoll, H. J., Van Cutsem, E., Stein, A., Valentini, V., Glimelius, B., Haustermans, K., Nordlinger, B., van de Velde, C. J., Balmana, J., Regula, J., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds236 · Cited by 1,510 · cited 1×
“• For patients who have Stage II colorectal cancer with a high risk of recurrence, the indications for adjuvant chemotherapy are considered after obtaining informed consent [51, 52] (CQ-14).”
BackgroundLièvre, A., Bachet, J.-B., Boige, V., Cayre, A., Le Corre, D., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,444
Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414325 · Cited by 1,431 · cited 8×
“⑤ The efficacy and safety of TAS-102 are evaluated on the basis of J-003 study and RECOURSE study.”
BackgroundInfluentialSelf-citationBenson, A. B., Schrag, D., Somerfield, M. R., Cohen, A. M., Figueredo, A. T., Flynn, P. J., Krzyzanowska, M. K., Maroun, J., McAllister, P., Van Cutsem, E., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.063 · Cited by 1,430 · cited 1×
“• For patients who have Stage II colorectal cancer with a high risk of recurrence, the indications for adjuvant chemotherapy are considered after obtaining informed consent [51, 52] (CQ-14).”
BackgroundSperduto, P. W., Kased, N., Roberge, D., Xu, Z., Shanley, R., Luo, X., Sneed, P. K., Chao, S. T., Weil, R. J., Suh, J., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.0527 · Cited by 1,425
Andrews, J., Guyatt, G., Oxman, A. D., Alderson, P., Dahm, P., Falck-Ytter, Y., Nasser, M., Meerpohl, J., Post, P. N., Kunz, R., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.03.013 · Cited by 1,416 · cited 1×
“Table 3 Strength of recommendation (Reference [24])”
Early colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Labianca, R., Nordlinger, B., Beretta, G. D., Mosconi, S., Mandalà, M., Cervantes, A., & Arnold, D. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt354 · Cited by 1,404
Van Cutsem, E., Tabernero, J., Lakomy, R., Prenen, H., Prausová, J., Macarulla, T., Ruff, P., van Hazel, G. A., Moiseyenko, V., Ferry, D., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8201 · Cited by 1,402
GRADE guidelines: 9. Rating up the quality of evidence
Guyatt, G. H., Oxman, A. D., Sultan, S., Glasziou, P., Akl, E. A., Alonso-Coello, P., Atkins, D., Kunz, R., Brozek, J., Montori, V., et al. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2011.06.004 · Cited by 1,336
Andrews, J. C., Schünemann, H. J., Oxman, A. D., Pottie, K., Meerpohl, J. J., Coello, P. A., Rind, D., Montori, V. M., Brito, J. P., Norris, S., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.02.003 · Cited by 1,315
Nordlinger, B., Sorbye, H., Glimelius, B., Poston, G. J., Schlag, P. M., Rougier, P., Bechstein, W. O., Primrose, J. N., Walpole, E. T., Finch-Jones, M., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70447-9 · Cited by 1,306
Liver resection for colorectal metastases.
Fong, Y., Cohen, A. M., Fortner, J. G., Enker, W. E., Turnbull, A. D., Coit, D. G., Marrero, A. M., Prasad, M., Blumgart, L. H., & Brennan, M. F. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.3.938 · Cited by 1,284
Cunningham, D., Pyrhönen, S., James, R. D., Punt, C. J., Hickish, T. F., Heikkila, R., Johannesen, T. B., Starkhammar, H., Topham, C. A., Awad, L., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02309-5 · Cited by 1,259 · cited 1×
“groups than in the best supportive care (BSC) groups that did not receive anticancer drugs [27–29].”
BackgroundCapecitabine as Adjuvant Treatment for Stage III Colon Cancer
Twelves, C., Wong, A., Nowacki, M. P., Abt, M., Burris, H., Carrato, A., Cassidy, J., Cervantes, A., Fagerberg, J., Georgoulias, V., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043116 · Cited by 1,248
Bujko, K., Nowacki, M. P., Nasierowska-Guttmejer, A., Michalski, W., Bebenek, M., & Kryj, M. (2006) · British Journal of Surgery · doi:10.1002/bjs.5506 · Cited by 1,244 · cited 1×
“In two trials (the exception being the short-course radiotherapy trial), the local recurrence rate was significantly lower in the preoperative chemoradiotherapy group, and there was no significant difference between the two groups in terms of sphincter preservation or survival rate [65–67].”
BackgroundFalcone, A., Ricci, S., Brunetti, I., Pfanner, E., Allegrini, G., Barbara, C., Crinò, L., Benedetti, G., Evangelista, W., Fanchini, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.09.0928 · Cited by 1,241 · cited 1×
“• FOLFOX (note 1) [57, 58] + Bmab [54] • CapeOX (note 2) + Bmab [59, 60] ▪ SOX + Bmab (note 3) [61] • FOLFIRI (note 4) [62, 63] + Bmab [64, 65] • FOLFOX + Cmab/Pmab [66, 67] • FOLFIRI + Cmab/Pmab [68, 69] • FOLFOXIRI (note 5) [70] ▪ FOLFOXIRI + Bmab [71, 72] • Infusional 5-FU + LV [73, 74] + Bmab [75, 76] • Cape [77,…”
Atkins, D., Eccles, M., Flottorp, S., Guyatt, G. H., Henry, D., Hill, S., Liberati, A., O'Connell, D., Oxman, A. D., Phillips, B., et al. (2004) · BMC Health Services Research · doi:10.1186/1472-6963-4-38 · Cited by 1,235
Peeters, K. C. M. J., Marijnen, C. A. M., Nagtegaal, I. D., Kranenbarg, E. K., Putter, H., Wiggers, T., Rutten, H., Pahlman, L., Glimelius, B., Leer, J. W., et al. (2007) · Annals of Surgery · doi:10.1097/01.sla.0000257358.56863.ce · Cited by 1,191 · cited 1×
“fractions in 1 week) ? TME with TME alone to investigate the significance of adding short-course radiotherapy to TME, the 5-year local control rate was significantly higher in the combination therapy group but there was no significant difference between the two groups in the 5-year survival rate [60, 61].”
BackgroundBennouna, J., Sastre, J., Arnold, D., Österlund, P., Greil, R., Van Cutsem, E., von Moos, R., Viéitez, J. M., Bouché, O., Borg, C., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70477-1 · Cited by 1,166 · cited 7×
“• FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89]”
InfluentialHoff, P. M., Ansari, R., Batist, G., Cox, J., Kocha, W., Kuperminc, M., Maroun, J., Walde, D., Weaver, C., Harrison, E., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.8.2282 · Cited by 1,130 · cited 11×
“(1) Patients appropriate for intensive therapy (a) When the patient has become refractory or intolerant to the first-line therapy, including OX • FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89] (b) When the patient has become refracto…”
InfluentialKhambata-Ford, S., Garrett, C. R., Meropol, N. J., Basik, M., Harbison, C. T., Wu, S., Wong, T. W., Huang, X., Takimoto, C. H., Godwin, A. K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5437 · Cited by 1,125 · cited 1×
“• The usefulness of anti-EGFR antibody drugs has been reported in metastatic colorectal cancer without KRAS gene mutations [38–41, 47, 53, 55, 85–90].”
BackgroundCremolini, C., Loupakis, F., Antoniotti, C., Lupi, C., Sensi, E., Lonardi, S., Mezi, S., Tomasello, G., Ronzoni, M., Zaniboni, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00122-9 · Cited by 1,092 · cited 6×
“(1) Patients appropriate for intensive therapy (a) When the patient has become refractory or intolerant to the first-line therapy, including OX • FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89] (b) When the patient has become refracto…”
InfluentialAdjuvant Therapy for Patients With Colon and Rectal Cancer
(1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450110090034 · Cited by 1,086
Efficacy of adjuvant fluorouracil and folinic acid in colon cancer
(1995) · The Lancet · doi:10.1016/s0140-6736(95)90696-7 · Cited by 1,066
Initial Therapy with FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer
Loupakis, F., Cremolini, C., Masi, G., Lonardi, S., Zagonel, V., Salvatore, L., Cortesi, E., Tomasello, G., Ronzoni, M., Spadi, R., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1403108 · Cited by 1,062 · cited 6×
“(1) Patients appropriate for intensive therapy (a) When the patient has become refractory or intolerant to the first-line therapy, including OX • FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89] (b) When the patient has become refracto…”
InfluentialKuebler, J. P., Wieand, H. S., O'Connell, M. J., Smith, R. E., Colangelo, L. H., Yothers, G., Petrelli, N. J., Findlay, M. P., Seay, T. E., Atkins, J. N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.2974 · Cited by 1,056 · cited 1×
“• Randomized controlled trials conducted in Europe and the United States have shown that the combination of intravenous infusion of 5-FU ? LV and L-OHP (FOLFOX4 and FLOX) used as postoperative adjuvant chemotherapy for stage III colon cancer provides an additional benefit in terms of prevention of recurrence and survi…”
BackgroundVan Cutsem, E., Twelves, C., Cassidy, J., Allman, D., Bajetta, E., Boyer, M., Bugat, R., Findlay, M., Frings, S., Jahn, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.21.4097 · Cited by 1,032 · cited 11×
“(1) Patients appropriate for intensive therapy (a) When the patient has become refractory or intolerant to the first-line therapy, including OX • FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89] (b) When the patient has become refracto…”
InfluentialPeeters, M., Price, T. J., Cervantes, A., Sobrero, A. F., Ducreux, M., Hotko, Y., André, T., Chan, E., Lordick, F., Punt, C. J. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6055 · Cited by 1,005
Rougier, P., Van Cutsem, E., Bajetta, E., Niederle, N., Possinger, K., Labianca, R., Navarro, M., Morant, R., Bleiberg, H., Wils, J., et al. (1998) · The Lancet · doi:10.1016/s0140-6736(98)03085-2 · Cited by 992
Borgelt, B., Gelber, R., Kramer, S., Brady, L. W., Chang, C. H., Davis, L. W., Perez, C. A., & Hendrickson, F. R. (1980) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(80)90195-9 · Cited by 953
Tabernero, J., Yoshino, T., Cohn, A. L., Obermannova, R., Bodoky, G., Garcia-Carbonero, R., Ciuleanu, T.-E., Portnoy, D. C., Van Cutsem, E., Grothey, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70127-0 · Cited by 952 · cited 5×
“• FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89]”
InfluentialSelf-citationSobrero, A. F., Maurel, J., Fehrenbacher, L., Scheithauer, W., Abubakr, Y. A., Lutz, M. P., Vega-Villegas, M. E., Eng, C., Steinhauer, E. U., Prausova, J., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1193 · Cited by 946 · cited 21×
“• FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89]”
InfluentialPeeters, K. C. M. J., van de Velde, C. J. H., Leer, J. W. H., Martijn, H., Junggeburt, J. M. C., Kranenbarg, E. K., Steup, W. H., Wiggers, T., Rutten, H. J., & Marijnen, C. A. M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.779 · Cited by 943 · cited 1×
“The incidences of sexual dysfunction and bowel dysfunction were higher in the preoperative radiation combination therapy group than in the surgeryalone group [113, 114].”
BackgroundNgan, S. Y., Burmeister, B., Fisher, R. J., Solomon, M., Goldstein, D., Joseph, D., Ackland, S. P., Schache, D., McClure, B., McLachlan, S.-A., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.9597 · Cited by 921
de Gramont, A., Bosset, J. F., Milan, C., Rougier, P., Bouché, O., Etienne, P. L., Morvan, F., Louvet, C., Guillot, T., François, E., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.808 · Cited by 908 · cited 1×
“• FOLFOX (note 1) [57, 58] + Bmab [54] • CapeOX (note 2) + Bmab [59, 60] ▪ SOX + Bmab (note 3) [61] • FOLFIRI (note 4) [62, 63] + Bmab [64, 65] • FOLFOX + Cmab/Pmab [66, 67] • FOLFIRI + Cmab/Pmab [68, 69] • FOLFOXIRI (note 5) [70] ▪ FOLFOXIRI + Bmab [71, 72] • Infusional 5-FU + LV [73, 74] + Bmab [75, 76] • Cape [77,…”
(2001) · The Lancet · doi:10.1016/s0140-6736(01)06409-1 · Cited by 870
Cassidy, J., Clarke, S., Díaz-Rubio, E., Scheithauer, W., Figer, A., Wong, R., Koski, S., Lichinitser, M., Yang, T.-S., Rivera, F., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9898 · Cited by 862 · cited 6×
“(1) Patients appropriate for intensive therapy (a) When the patient has become refractory or intolerant to the first-line therapy, including OX • FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89] (b) When the patient has become refracto…”
InfluentialFuchs, C. S., Marshall, J., Mitchell, E., Wierzbicki, R., Ganju, V., Jeffery, M., Schulz, J., Richards, D., Soufi-Mahjoubi, R., Wang, B., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.3357 · Cited by 851 · cited 6×
“(1) Patients appropriate for intensive therapy (a) When the patient has become refractory or intolerant to the first-line therapy, including OX • FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89] (b) When the patient has become refracto…”
InfluentialGRADE guidelines: 12. Preparing Summary of Findings tables—binary outcomes
Guyatt, G. H., Oxman, A. D., Santesso, N., Helfand, M., Vist, G., Kunz, R., Brozek, J., Norris, S., Meerpohl, J., Djulbegovic, B., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.01.012 · Cited by 836
Hughes, K. S., Simon, R., Songhorabodi, S., Adson, M. A., Dm, I., Fortner, J. G., Maclean, B. J., Jh, F., Daly, J. M., & Fitzherbert, D. (1986) · PubMed · Cited by 821
Endoscopic Mucosal Resection of Flat and Depressed Types of Early Colorectal Cancer
Kudo, S. (1993) · Endoscopy · doi:10.1055/s-2007-1010367 · Cited by 820 · cited 1×
“It is mainly used for superficial tumors and large sessile lesions Note 3: ESD—In this technique, the lesion is elevated by local injection of a liquid such as sodium hyaluronate solution into the submucosa of the perilesional area; then, circumferential incision of the mucosa surrounding the lesion and dissection of…”
MethodFrancois, Y., Nemoz, C. J., Baulieux, J., Vignal, J., Grandjean, J.-P., Partensky, C., Souquet, J. C., Adeleine, P., & Gerard, J.-P. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2396 · Cited by 815 · cited 1×
“When the purpose of the preoperative radiotherapy is sphincter preservation, it is desirable to perform surgery after allowing an appropriate period for the tumor to decrease in size (6–8 weeks after the completion of radiotherapy) [115].”
BackgroundA prospective, multicenter study of 1111 colorectal endoscopic submucosal dissections (with video)
Saito, Y., Uraoka, T., Yamaguchi, Y., Hotta, K., Sakamoto, N., Ikematsu, H., Fukuzawa, M., Kobayashi, N., Nasu, J., Michida, T., et al. (2010) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2010.08.004 · Cited by 787
Self-citationHaller, D. G., Tabernero, J., Maroun, J., de Braud, F., Price, T., Van Cutsem, E., Hill, M., Gilberg, F., Rittweger, K., & Schmoll, H.-J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.6297 · Cited by 784
GRADE guidelines: 13. Preparing Summary of Findings tables and evidence profiles—continuous outcomes
Guyatt, G. H., Thorlund, K., Oxman, A. D., Walter, S. D., Patrick, D., Furukawa, T. A., Johnston, B. C., Karanicolas, P., Akl, E. A., Vist, G., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.08.001 · Cited by 772
Aschele, C., Cionini, L., Lonardi, S., Pinto, C., Cordio, S., Rosati, G., Artale, S., Tagliagambe, A., Ambrosini, G., Rosetti, P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4911 · Cited by 763
Guyatt, G., Oxman, A. D., Sultan, S., Brozek, J., Glasziou, P., Alonso-Coello, P., Atkins, D., Kunz, R., Montori, V., Jaeschke, R., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.01.006 · Cited by 762
(1995) · PubMed · Cited by 759
Risk factors for an adverse outcome in early invasive colorectal carcinoma
Ueno, H., Mochizuki, H., Hashiguchi, Y., Shimazaki, H., Aida, S., Hase, K., Matsukuma, S., Kanai, T., Kurihara, H., Ozawa, K., et al. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.04.022 · Cited by 758 · cited 3×
“[Definition of tumor budding] [136] A cancer cell nest consisting of one or fewer than five cells that infiltrates the interstitium at the invasive margin of the cancer.”
BackgroundSelf-citationPreoperative Radiotherapy for Resectable Rectal Cancer: A Meta-analysis
Cammà, C., Giunta, M., Fiorica, F., Pagliaro, L., Craxì, A., & Cottone, M. (2000) · JAMA · doi:10.1001/jama.284.8.1008 · Cited by 754 · cited 1×
“However, there is controversy as to whether there is improvement in the survival rate [108, 109].”
BackgroundGérard, J.-P., Azria, D., Gourgou-Bourgade, S., Martel-Laffay, I., Hennequin, C., Etienne, P.-L., Vendrely, V., François, E., de La Roche, G., Bouché, O., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.8376 · Cited by 747
Di Fiore, F., Blanchard, F., Charbonnier, F., Le Pessot, F., Lamy, A., Galais, M. P., Bastit, L., Killian, A., Sesboüé, R., Tuech, J. J., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603685 · Cited by 734 · cited 1×
“• The usefulness of anti-EGFR antibody drugs has been reported in metastatic colorectal cancer without KRAS gene mutations [38–41, 47, 53, 55, 85–90].”
BackgroundRödel, C., Liersch, T., Becker, H., Fietkau, R., Hohenberger, W., Hothorn, T., Graeven, U., Arnold, D., Lang-Welzenbach, M., Raab, H.-R., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70187-0 · Cited by 696 · cited 1×
“In randomized controlled trials into the efficacy of adding OX to pyrimidine fluoride as a combination chemotherapy in the preoperative chemoradiotherapy, OX increased harmful phenomena in three tests, but demonstrated no efficacy in regard to pCR ratio, localized control ratio and survival [120, 122–124]; moreover, i…”
BackgroundCancer pain relief and palliative care
Akinsanya, C. Y. (1992) · Nurse Education Today · doi:10.1016/0260-6917(92)90050-x · Cited by 692
A multi-institutional experience with stereotactic radiosurgery for solitary brain metastasis
Flickinger, J. C., Kondziolka, D., Dade Lunsford, L., Coffey, R. J., Goodman, M. L., Shaw, E. G., Robert Hudgins, W., Weiner, R., Harsh, G. R., Sneed, P. K., et al. (1994) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(94)90098-1 · Cited by 690
Hurwitz, H. I., Fehrenbacher, L., Hainsworth, J. D., Heim, W., Berlin, J., Holmgren, E., Hambleton, J., Novotny, W. F., & Kabbinavar, F. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.10.017 · Cited by 688 · cited 7×
“(1) Patients appropriate for intensive therapy (a) When the patient has become refractory or intolerant to the first-line therapy, including OX • FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89] (b) When the patient has become refracto…”
InfluentialKitajima, K., Fujimori, T., Fujii, S., Takeda, J., Ohkura, Y., Kawamata, H., Kumamoto, T., Ishiguro, S., Kato, Y., Shimoda, T., et al. (2004) · Journal of Gastroenterology · doi:10.1007/s00535-004-1339-4 · Cited by 663 · cited 1×
“Factors such as the depth of submucosal invasion (SM invasion depth) [137], histological type, such as poorly differentiated adenocarcinoma, signet-ring cell carcinoma, and mucinous carcinoma [136], the presence of a poorlydifferentiated area and muconodules at the site of deepest invasion, budding, and vascular invas…”
BackgroundSelf-citationPalliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis
Colorectal Cancer Collaborative Group (2000) · BMJ · doi:10.1136/bmj.321.7260.531 · Cited by 662
Yothers, G., O'Connell, M. J., Allegra, C. J., Kuebler, J. P., Colangelo, L. H., Petrelli, N. J., & Wolmark, N. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.4539 · Cited by 656
Scheithauer, W., Rosen, H., Kornek, G. V., Sebesta, C., & Depisch, D. (1993) · BMJ · doi:10.1136/bmj.306.6880.752 · Cited by 654 · cited 6×
“(1) Patients appropriate for intensive therapy (a) When the patient has become refractory or intolerant to the first-line therapy, including OX • FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89] (b) When the patient has become refracto…”
InfluentialRenehan, A. G., Egger, M., Saunders, M. P., & O'Dwyer, S. T. (2002) · BMJ · doi:10.1136/bmj.324.7341.813 · Cited by 651
Marijnen, C. A. M., van de Velde, C. J. H., Putter, H., van den Brink, M., Maas, C. P., Martijn, H., Rutten, H. J., Wiggers, T., Kranenbarg, E. K., Leer, J.-W. H., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.256 · Cited by 650 · cited 1×
“The incidences of sexual dysfunction and bowel dysfunction were higher in the preoperative radiation combination therapy group than in the surgeryalone group [113, 114].”
BackgroundCancer Pain Relief and Palliative Care: Report of a WHO Expert Committee
(1991) · Annals of Internal Medicine · doi:10.7326/0003-4819-114-8-712_4 · Cited by 646 · cited 1×
“Cancer pain relief and palliative care (1990) Report of a WHO expert committee.”
BackgroundRothenberg, M. L., Oza, A. M., Bigelow, R. H., Berlin, J. D., Marshall, J. L., Ramanathan, R. K., Hart, L. L., Gupta, S., Garay, C. A., Burger, B. G., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.11.126 · Cited by 646 · cited 12×
“• FOLFOX [62, 90] + Bmab [85, 91] • CapeOX (note 2) [92] + Bmab [85] ▪ SOX + Bmab ▪ FOLFOX + Cmab/Bmab”
InfluentialFollow-up strategies for patients treated for non-metastatic colorectal cancer
Jeffery, M., Hickey, B. E., Hider, P. N., & See, A. M. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002200.pub3 · Cited by 640 · cited 1×
“Meta-analyses of RCTs conducted in Europe and the United States have shown that surveillance after curative surgical resection of colorectal cancer contributes to improving the resection rate of recurrent tumors and to improving the prognosis [70–74] (CQ-19).”
BackgroundJapanese Research Society for Cancer of the Colon and Rectum, & Dennosuke, J. (1983) · The Japanese Journal of Surgery · doi:10.1007/bf02469505 · Cited by 627
Complete Response of Colorectal Liver Metastases After Chemotherapy: Does It Mean Cure?
Benoist, S., Brouquet, A., Penna, C., Julié, C., El Hajjam, M., Chagnon, S., Mitry, E., Rougier, P., & Nordlinger, B. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.8727 · Cited by 607
Niekel, M. C., Bipat, S., & Stoker, J. (2010) · Radiology · doi:10.1148/radiol.10100729 · Cited by 584
Mitry, E., Fields, A. L. A., Bleiberg, H., Labianca, R., Portier, G., Tu, D., Nitti, D., Torri, V., Elias, D., O'Callaghan, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.17.3781 · Cited by 583 · cited 1×
“4 Adjuvant therapy subsequent to the resection of distant metastasis • The efficacy and safety of adjuvant chemotherapy following the resection of distant metastasis in colorectal cancer have not been established, and no randomized controlled trials have been implemented regarding whether or not it extends survival [3…”
BackgroundPortier, G., Elias, D., Bouche, O., Rougier, P., Bosset, J.-F., Saric, J., Belghiti, J., Piedbois, P., Guimbaud, R., Nordlinger, B., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.8353 · Cited by 579 · cited 1×
“4 Adjuvant therapy subsequent to the resection of distant metastasis • The efficacy and safety of adjuvant chemotherapy following the resection of distant metastasis in colorectal cancer have not been established, and no randomized controlled trials have been implemented regarding whether or not it extends survival [3…”
BackgroundUse of GRADE grid to reach decisions on clinical practice guidelines when consensus is elusive
Jaeschke, R., Guyatt, G. H., Dellinger, P., Schunemann, H., Levy, M. M., Kunz, R., Norris, S., Bion, J., & for the GRADE working group (2008) · BMJ · doi:10.1136/bmj.a744 · Cited by 577
Desch, C. E., Benson, A. B., Somerfield, M. R., Flynn, P. J., Krause, C., Loprinzi, C. L., Minsky, B. D., Pfister, D. G., Virgo, K. S., & Petrelli, N. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.0063 · Cited by 559
FORTNER, J. G., SILVA, J. S., GOLBEY, R. B., COX, E. B., & MACLEAN, B. J. (1984) · Annals of Surgery · doi:10.1097/00000658-198403000-00010 · Cited by 532
Påhlman, L. (2001) · The Lancet · Cited by 529
Stereotactic body radiotherapy for oligometastases
Tree, A. C., Khoo, V. S., Eeles, R. A., Ahmed, M., Dearnaley, D. P., Hawkins, M. A., Huddart, R. A., Nutting, C. M., Ostler, P. J., & van As, N. J. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70510-7 · Cited by 524 · cited 1×
“• Even if the patient cannot tolerate surgery, stereotactic body radiotherapy is considered if the primary tumor and extrapulmonary metastases are controlled or can be controlled and the number of lung metastases within 5 cm in diameter is no more than three [48].”
BackgroundHofheinz, R.-D., Wenz, F., Post, S., Matzdorff, A., Laechelt, S., Hartmann, J. T., Müller, L., Link, H., Moehler, M., Kettner, E., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70116-x · Cited by 509 · cited 1×
“A randomized controlled trial of 5-FU versus Cape combination chemotherapy in the preoperative chemoradiotherapy indicated that the two drugs had the same level of efficacy and safety [120, 121].”
BackgroundPetrelli, N., Herrera, L., Rustum, Y., Burke, P., Creaven, P., Stulc, J., Emrich, L. J., & Mittelman, A. (1987) · Journal of Clinical Oncology · doi:10.1200/jco.1987.5.10.1559 · Cited by 450
Meta-Analysis Group In Cancer (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.5.252 · Cited by 441 · cited 1×
“2 Although hepatic arterial infusion therapy shows high response rates for liver metastasis, it does not demonstrate any survival benefit compared with systemic chemotherapy [101].”
BackgroundWong, S. L., Mangu, P. B., Choti, M. A., Crocenzi, T. S., Dodd, G. D., Dorfman, G. S., Eng, C., Fong, Y., Giusti, A. F., Lu, D., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.4450 · Cited by 433 · cited 1×
“There is a high rate of recurrence in comparison to resection, however, and long-term survival is reported to be poor [46], so it is not recommended as an alternative to surgical resection [47] (CQ-12).”
BackgroundClinical Outcome of the ACCORD 12/0405 PRODIGE 2 Randomized Trial in Rectal Cancer
Gérard, J.-P., Azria, D., Gourgou-Bourgade, S., Martel-Lafay, I., Hennequin, C., Etienne, P.-L., Vendrely, V., François, E., de La Roche, G., Bouché, O., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.8771 · Cited by 430
Indication and Benefit of Pelvic Sidewall Dissection for Rectal Cancer
Sugihara, K., Kobayashi, H., Kato, T., Mori, T., Mochizuki, H., Kameoka, S., Shirouzu, K., & Muto, T. (2006) · Diseases of the Colon & Rectum · doi:10.1007/s10350-006-0714-z · Cited by 427 · cited 1×
“After performing lateral lymph node dissection for the above mentioned indication, it is expected that the risk of intrapelvic recurrence decreases by 50%, and the 5-year survival rate improves by 8–9% [34].”
BackgroundSelf-citationCady, B., Jenkins, R. L., Steele, G. D., Lewis, W. D., Stone, M. D., McDermott, W. V., Jessup, J. M., Bothe, A., Lalor, P., Lovett, E. J., et al. (1998) · Annals of Surgery · doi:10.1097/00000658-199804000-00019 · Cited by 423
Tebbutt, N. C., Wilson, K., Gebski, V. J., Cummins, M. M., Zannino, D., van Hazel, G. A., Robinson, B., Broad, A., Ganju, V., Ackland, S. P., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.7723 · Cited by 413 · cited 6×
“(1) Patients appropriate for intensive therapy (a) When the patient has become refractory or intolerant to the first-line therapy, including OX • FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89] (b) When the patient has become refracto…”
InfluentialIncorporating considerations of resources use into grading recommendations
Guyatt, G. H., Oxman, A. D., Kunz, R., Jaeschke, R., Helfand, M., Liberati, A., Vist, G. E., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39504.506319.80 · Cited by 412
BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer
Yokota, T., Ura, T., Shibata, N., Takahari, D., Shitara, K., Nomura, M., Kondo, C., Mizota, A., Utsunomiya, S., Muro, K., et al. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.19 · Cited by 401
Self-citationGonzalez, M., Poncet, A., Combescure, C., Robert, J., Ris, H. B., & Gervaz, P. (2013) · Annals of Surgical Oncology · doi:10.1245/s10434-012-2726-3 · Cited by 398
NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer
(1990) · JAMA · doi:10.1001/jama.264.11.1444 · Cited by 394
Follow-up of patients with curatively resected colorectal cancer: a practice guideline
Figueredo, A., Rumble, R. B., Maroun, J., Earle, C. C., Cummings, B., McLeod, R., Zuraw, L., Zwaal, C., & the members of the Gastrointestinal Cancer Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care (2003) · BMC Cancer · doi:10.1186/1471-2407-3-26 · Cited by 392 · cited 1×
“Meta-analyses of RCTs conducted in Europe and the United States have shown that surveillance after curative surgical resection of colorectal cancer contributes to improving the resection rate of recurrent tumors and to improving the prognosis [70–74] (CQ-19).”
BackgroundHaller, D. G., Catalano, P. J., Macdonald, J. S., O'Rourke, M. A., Frontiera, M. S., Jackson, D. V., & Mayer, R. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.5686 · Cited by 391 · cited 1×
“Note: The Roswell Park Memorial Institute (RPMI) method of 5-FU + LV therapy as adjuvant chemotherapy (drip infusion of l-LV 250 mg/m(2) administered for 2 h; intravenous infusion of 5-FU 500 mg/m(2) slowly administered within 3 min at 1 h after initiating l-LV administration; and once weekly administration for six co…”
MethodSeymour, M. T., Brown, S. R., Middleton, G., Maughan, T., Richman, S., Gwyther, S., Lowe, C., Seligmann, J. F., Wadsley, J., Maisey, N., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70163-3 · Cited by 388
Meyerhardt, J. A., Mangu, P. B., Flynn, P. J., Korde, L., Loprinzi, C. L., Minsky, B. D., Petrelli, N. J., Ryan, K., Schrag, D. H., Wong, S. L., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.50.7442 · Cited by 369
Fujita, S., Akasu, T., Mizusawa, J., Saito, N., Kinugasa, Y., Kanemitsu, Y., Ohue, M., Fujii, S., Shiozawa, M., Yamaguchi, T., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70158-4 · Cited by 352
Self-citationFollow-Up After Curative Resection of Colorectal Cancer: A Meta-Analysis
Tjandra, J. J., & Chan, M. K. Y. (2007) · Diseases of the Colon & Rectum · doi:10.1007/s10350-007-9030-5 · Cited by 342 · cited 1×
“Meta-analyses of RCTs conducted in Europe and the United States have shown that surveillance after curative surgical resection of colorectal cancer contributes to improving the resection rate of recurrent tumors and to improving the prognosis [70–74] (CQ-19).”
BackgroundAdjuvant therapy for colon and rectal cancer
Metzger, U. (1990) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(90)90136-h · Cited by 335
Kurtz, J. M., Gelber, R., Brady, L. W., Carella, R. J., & Cooper, J. S. (1981) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(81)90005-5 · Cited by 331
Pulmonary metastasectomy for 165 patients with colorectal carcinoma: A prognostic assessment
Saito, Y., Omiya, H., Kohno, K., Kobayashi, T., Itoi, K., Teramachi, M., Sasaki, M., Suzuki, H., Takao, H., & Nakade, M. (2002) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1067/mtc.2002.125165 · Cited by 330
Self-citationLembersky, B. C., Wieand, H. S., Petrelli, N. J., O'Connell, M. J., Colangelo, L. H., Smith, R. E., Seay, T. E., Giguere, J. K., Marshall, M. E., Jacobs, A. D., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7498 · Cited by 328
Yoshino, T., Mizunuma, N., Yamazaki, K., Nishina, T., Komatsu, Y., Baba, H., Tsuji, A., Yamaguchi, K., Muro, K., Sugimoto, N., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70345-5 · Cited by 326 · cited 8×
“⑤ The efficacy and safety of TAS-102 are evaluated on the basis of J-003 study and RECOURSE study.”
BackgroundInfluentialSelf-citationDouillard, J.-Y., Hoff, P. M., Skillings, J. R., Eisenberg, P., Davidson, N., Harper, P., Vincent, M. D., Lembersky, B. C., Thompson, S., Maniero, A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.04.123 · Cited by 323
Follow-Up of Patients with Colorectal Cancer A Meta-Analysis
Bruinvels, D. J., Stiggelbout, A. M., Kievit, J., van Houwellngen, H. C., F. Habbema, J. D., & van de Velde, C. J. H. (1994) · Annals of Surgery · doi:10.1097/00000658-199402000-00009 · Cited by 322 · cited 1×
“1 3 gery, that approximately 70% of the recurrences were detected within 2 years after surgery [132, 133]; and that in most patients the recurrences were detected within 5 years after surgery [133].”
BackgroundPetrowsky, H., Gonen, M., Jarnagin, W., Lorenz, M., DeMatteo, R., Heinrich, S., Encke, A., Blumgart, L., & Fong, Y. (2002) · Annals of Surgery · doi:10.1097/00000658-200206000-00015 · Cited by 320
Melanoma, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology
Coit, D. G., Thompson, J. A., Algazi, A., Andtbacka, R., Bichakjian, C. K., Carson, W. E., Daniels, G. A., DiMaio, D., Ernstoff, M., Fields, R. C., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0051 · Cited by 306
Colorectal lung metastases: Results of surgical excision
McAfee, M. K., Allen, M. S., Trastek, V. F., Ilstrup, D. M., Deschamps, C., & Pairolero, P. C. (1992) · The Annals of Thoracic Surgery · doi:10.1016/0003-4975(92)91435-c · Cited by 301
Allen, P. J., Kemeny, N., Jarnagin, W., DeMatteo, R., Blumgart, L., & Fong, Y. (2003) · Journal of Gastrointestinal Surgery · doi:10.1016/s1091-255x(02)00121-x · Cited by 301
Adam, R., Wicherts, D. A., de Haas, R. J., Aloia, T., Lévi, F., Paule, B., Guettier, C., Kunstlinger, F., Delvart, V., Azoulay, D., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.7471 · Cited by 300
Long-term Outcomes After Resection for Submucosal Invasive Colorectal Cancers
Ikematsu, H., Yoda, Y., Matsuda, T., Yamaguchi, Y., Hotta, K., Kobayashi, N., Fujii, T., Oono, Y., Sakamoto, T., Nakajima, T., et al. (2013) · Gastroenterology · doi:10.1053/j.gastro.2012.12.003 · Cited by 296
Self-citationPalliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis
姚方, & 陆星华 (2001) · doi:10.3760/cma.j.issn.1007-9742.2001.01.130 · Cited by 287
GRADE guidelines: 10. Considering resource use and rating the quality of economic evidence
Brunetti, M., Shemilt, I., Pregno, S., Vale, L., Oxman, A. D., Lord, J., Sisk, J., Ruiz, F., Hill, S., Guyatt, G. H., et al. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2012.04.012 · Cited by 286
Moriya, Y., Hojo, K., Sawada, T., & Koyama, Y. (1989) · Diseases of the Colon & Rectum · doi:10.1007/bf02553486 · Cited by 282
Lung Resection for Colorectal Metastases: 10-Year Results
McCormack, P. M. (1992) · Archives of Surgery · doi:10.1001/archsurg.1992.01420120037006 · Cited by 278
Carmichael, J., Popiela, T., Radstone, D., Falk, S., Borner, M., Oza, A., Skovsgaard, T., Munier, S., & Martin, C. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.10.129 · Cited by 268
Cappuzzo, F., Finocchiaro, G., Rossi, E., Jänne, P. A., Carnaghi, C., Calandri, C., Bencardino, K., Ligorio, C., Ciardiello, F., Pressiani, T., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm492 · Cited by 267 · cited 1×
“• The usefulness of anti-EGFR antibody drugs has been reported in metastatic colorectal cancer without KRAS gene mutations [38–41, 47, 53, 55, 85–90].”
BackgroundKokudo, N., Miki, Y., Sugai, S., Yanagisawa, A., Kato, Y., Sakamoto, Y., Yamamoto, J., Yamaguchi, T., Muto, T., & Makuuchi, M. (2002) · Archives of Surgery · doi:10.1001/archsurg.137.7.833 · Cited by 262
Self-citationUeno, M., Oya, M., Azekura, K., Yamaguchi, T., & Muto, T. (2005) · British Journal of Surgery · doi:10.1002/bjs.4975 · Cited by 259
Self-citationAkiyoshi, T., Watanabe, T., Miyata, S., Kotake, K., Muto, T., & Sugihara, K. (2012) · Annals of Surgery · doi:10.1097/sla.0b013e3182565d9d · Cited by 258
Self-citationTanaka, S., Oka, S., & Chayama, K. (2008) · Journal of Gastroenterology · doi:10.1007/s00535-008-2223-4 · Cited by 253 · cited 8×
“• EMRC (EMR using a cap) is reported to involve a high risk of perforation when used for colon lesions.”
BackgroundInfluentialSelf-citationYamada, Y., Takahari, D., Matsumoto, H., Baba, H., Nakamura, M., Yoshida, K., Yoshida, M., Iwamoto, S., Shimada, K., Komatsu, Y., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70490-x · Cited by 248 · cited 1×
“• FOLFOX (note 1) [57, 58] + Bmab [54] • CapeOX (note 2) + Bmab [59, 60] ▪ SOX + Bmab (note 3) [61] • FOLFIRI (note 4) [62, 63] + Bmab [64, 65] • FOLFOX + Cmab/Pmab [66, 67] • FOLFIRI + Cmab/Pmab [68, 69] • FOLFOXIRI (note 5) [70] ▪ FOLFOXIRI + Bmab [71, 72] • Infusional 5-FU + LV [73, 74] + Bmab [75, 76] • Cape [77,…”
Self-citationLymphatic spread and its prognostic value in patients with rectal cancer
Hojo, K., Koyama, Y., & Moriya, Y. (1982) · The American Journal of Surgery · doi:10.1016/0002-9610(82)90018-6 · Cited by 243
Current status of endoscopic resection strategy for large, early colorectal neoplasia in Japan
Nakajima, T., Saito, Y., Tanaka, S., Iishi, H., Kudo, S.-E., Ikematsu, H., Igarashi, M., Saitoh, Y., Inoue, Y., Kobayashi, K., et al. (2013) · Surgical Endoscopy · doi:10.1007/s00464-013-2903-x · Cited by 243
Self-citationPulmonary resection for metastatic colorectal cancer: Experiences with 159 patients
Okumura, S., Kondo, H., Tsuboi, M., Nakayama, H., Asamura, H., Tsuchiya, R., & Naruke, T. (1996) · The Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/s0022-5223(96)70085-5 · Cited by 239
Kato, T., Yasui, K., Hirai, T., Kanemitsu, Y., Mori, T., Sugihara, K., Mochizuki, H., & Yamamoto, J. (2003) · PubMed · doi:10.1097/01.dcr.0000089106.71914.00 · Cited by 237
Self-citationKnowledge and attitude on screening mammography among low-literate, low-income women
Davis, T. C., Arnold, C., Berkel, H. (., Nandy, I., Jackson, R. H., & Glass, J. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19961101)78:9<1912::aid-cncr11>3.0.co;2-0 · Cited by 230
Self-citationLong-Term Effect of Preoperative Radiation Therapy on Anorectal Function
Pollack, J., Holm, T., Cedermark, B., Holmström, B., & Mellgren, A. (2006) · Diseases of the Colon & Rectum · doi:10.1007/s10350-005-0296-1 · Cited by 226
Systematic review of outcomes after intersphincteric resection for low rectal cancer
Martin, S. T., Heneghan, H. M., & Winter, D. C. (2012) · British Journal of Surgery · doi:10.1002/bjs.8677 · Cited by 226
Nordlinger, B., Vaillant, J. C., Guiguet, M., Balladur, P., Paris, F., Bachellier, P., & Jaeck, D. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.7.1491 · Cited by 224
Colorectal metastasis (liver and lung)
Penna, C., & Nordlinger, B. (2002) · Surgical Clinics of North America · doi:10.1016/s0039-6109(02)00051-8 · Cited by 217
Fuchs, C. S., Marshall, J., & Barrueco, J. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.5390 · Cited by 217 · cited 6×
“(1) Patients appropriate for intensive therapy (a) When the patient has become refractory or intolerant to the first-line therapy, including OX • FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89] (b) When the patient has become refracto…”
InfluentialMuro, K., Boku, N., Shimada, Y., Tsuji, A., Sameshima, S., Baba, H., Satoh, T., Denda, T., Ina, K., Nishina, T., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70181-9 · Cited by 215 · cited 1×
“• FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89]”
Self-citationLateral node dissection and total mesorectal excision for rectal cancer
Takahashi, T., Ueno, M., Azekura, K., & Ohta, H. (2000) · Diseases of the Colon & Rectum · doi:10.1007/bf02237228 · Cited by 213
De Oliveira, E. (2003) · PubMed · Cited by 212
Surgical resection of pulmonary metastases from colorectal cancer. 10-year follow-up
Goya, T., Miyazawa, N., Kondo, H., Tsuchiya, R., Naruke, T., & Suemasu, K. (1989) · Cancer · doi:10.1002/1097-0142(19891001)64:7<1418::aid-cncr2820640709>3.0.co;2-n · Cited by 208
Follow-up of patients with colorectal cancer
Kievit, J. (2002) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00061-8 · Cited by 206
Follow-up strategies for patients treated for non-metastatic colorectal cancer
Jeffery, M., Hickey, B. E., & Hider, P. N. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002200.pub2 · Cited by 205
Outcomes after Resection of Synchronous or Metachronous Hepatic and Pulmonary Colorectal Metastases
Miller, G., Biernacki, P., Kemeny, N. E., Gonen, M., Downey, R., Jarnagin, W. R., D’Angelica, M., Fong, Y., Blumgart, L. H., & DeMatteo, R. P. (2007) · Journal of the American College of Surgeons · doi:10.1016/j.jamcollsurg.2007.04.039 · Cited by 203
Pattern of recurrence in liver resection for colorectal secondaries
Ekberg, H., Tranberg, K. ‐., Andersson, R., Lundstedt, C., Hägerstrand, I., Ranstam, J., & Bengmark, S. (1987) · World Journal of Surgery · doi:10.1007/bf01655821 · Cited by 203
Gastrointestinal cancer and brain metastasis: A rare and ominous sign
Go, P. H., Klaassen, Z., Meadows, M. C., & Chamberlain, R. S. (2011) · Cancer · doi:10.1002/cncr.25940 · Cited by 199
Yamamoto, J., Sugihara, K., Kosuge, T., Takayama, T., Shimada, K., Yamasaki, S., Sakamoto, M., & Hirohashi, S. (1995) · Annals of Surgery · doi:10.1097/00000658-199501000-00009 · Cited by 199
Self-citationRothenberg, M. L., Cox, J. V., Butts, C., Navarro, M., Bang, Y.-J., Goel, R., Gollins, S., Siu, L. L., Laguerre, S., & Cunningham, D. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn370 · Cited by 198 · cited 1×
“• FOLFOX [62, 90] + Bmab [85, 91] • CapeOX (note 2) [92] + Bmab [85] ▪ SOX + Bmab ▪ FOLFOX + Cmab/Bmab”
Prediction of Prognosis and Surgical Indications for Pulmonary Metastasectomy From Colorectal Cancer
Iizasa, T., Suzuki, M., Yoshida, S., Motohashi, S., Yasufuku, K., Iyoda, A., Shibuya, K., Hiroshima, K., Nakatani, Y., & Fujisawa, T. (2006) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2006.02.027 · Cited by 195
Roh, M. S., Yothers, G. A., O'Connell, M. J., Beart, R. W., Pitot, H. C., Shields, A. F., Parda, D. S., Sharif, S., Allegra, C. J., Petrelli, N. J., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.3503 · Cited by 194 · cited 1×
“A randomized controlled trial of 5-FU versus Cape combination chemotherapy in the preoperative chemoradiotherapy indicated that the two drugs had the same level of efficacy and safety [120, 121].”
BackgroundRisk factors for faecal incontinence after rectal cancer treatment
cooperative clinical investigators of the Dutch Total Mesorectal Excision trial, Lange, M. M., den Dulk, M., Bossema, E. R., Maas, C. P., Peeters, K. C. M. J., Rutten, H. J., Klein Kranenbarg, E., Marijnen, C. A. M., & van de Velde, C. J. H. (2007) · British Journal of Surgery · doi:10.1002/bjs.5819 · Cited by 190
Pestieau, S. R., & Sugarbaker, P. H. (2000) · Diseases of the Colon & Rectum · doi:10.1007/bf02236627 · Cited by 189
Seki, T., Wakabayashi, M., Nakagawa, T., Imamura, M., Tamai, T., Nishimura, A., Yamashiki, N., Okamura, A., & Inoue, K. (1999) · Cancer · doi:10.1002/(sici)1097-0142(19990415)85:8<1694::aid-cncr8>3.0.co;2-3 · Cited by 188
Lam, V. W. T., Spiro, C., Laurence, J. M., Johnston, E., Hollands, M. J., Pleass, H. C. C., & Richardson, A. J. (2012) · Annals of Surgical Oncology · doi:10.1245/s10434-011-2061-0 · Cited by 186 · cited 1×
“• Systemic chemotherapy is effective in regard to cases of inoperable liver metastasis, with some cases demonstrating that curative resection may become possible [41, 42] (CQ-9).”
BackgroundAuer, R. C., White, R. R., Kemeny, N. E., Schwartz, L. H., Shia, J., Blumgart, L. H., DeMatteo, R. P., Fong, Y., Jarnagin, W. R., & D'Angelica, M. I. (2010) · Cancer · doi:10.1002/cncr.24912 · Cited by 186
FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer
Loupakis, F., Cremolini, C., Salvatore, L., Masi, G., Sensi, E., Schirripa, M., Michelucci, A., Pfanner, E., Brunetti, I., Lupi, C., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2013.08.024 · Cited by 186
Surgical treatment of hepatic and pulmonary metastases from colorectal cancers
Regnard, J.-F., Grunenwald, D., Spaggiari, L., Girard, P., Elias, D., Ducreux, M., Baldeyrou, P., & Levasseur, P. (1998) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(98)00269-0 · Cited by 180 · cited 1×
“1 There are reports showing the efficacy of hepatectomy in patients who have controllable extrahepatic metastases (mainly lung metastases) in addition to liver metastases [35, 36, 39, 43] (CQ-7).”
BackgroundWolmark, N., Wieand, S., Kuebler, J. P., Colangelo, L., & Smith, R. E. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.lba3500 · Cited by 176
Resection of both hepatic and pulmonary metastases in patients with colorectal carcinoma
Murata, S., Moriya, Y., Akasu, T., Fujita, S., & Sugihara, K. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980915)83:6<1086::aid-cncr6>3.0.co;2-6 · Cited by 170
Self-citationLong-Term Results After Repeated Surgical Removal of Pulmonary Metastases
Kandioler, D., Krömer, E., Tüchler, H., End, A., Müller, M. R., Wolner, E., & Eckersberger, F. (1998) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(98)00019-8 · Cited by 164
Research works printed but not linked: 1
- Beppu TMT Maeda K Microwave coagulation therapy for metastatic liver tumor Surg Ther 2000 83 237 242
Cited by
Hashiguchi, Y., Muro, K., Saito, Y., Ito, Y., Ajioka, Y., Hamaguchi, T., Hasegawa, K., Hotta, K., Ishida, H., Ishiguro, M., et al. (2020) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01485-z · Cited by 1,922
Self-citationRenehan, A. G., Malcomson, L., Emsley, R., Gollins, S., Maw, A., Myint, A. S., Rooney, P. S., Susnerwala, S., Blower, A., Saunders, M. P., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00467-2 · Cited by 801
Japanese Society for Cancer of the Colon and Rectum (2019) · Journal of the Anus, Rectum and Colon · doi:10.23922/jarc.2019-018 · Cited by 696
Self-citationAdam, R., de Gramont, A., Figueras, J., Kokudo, N., Kunstlinger, F., Loyer, E., Poston, G., Rougier, P., Rubbia-Brandt, L., Sobrero, A., et al. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.06.006 · Cited by 607
Self-citationJGES guidelines for colorectal endoscopic submucosal dissection/endoscopic mucosal resection
Tanaka, S., Kashida, H., Saito, Y., Yahagi, N., Yamano, H., Saito, S., Hisabe, T., Yao, T., Watanabe, M., Yoshida, M., et al. (2015) · Digestive Endoscopy · doi:10.1111/den.12456 · Cited by 597
Self-citation
Metadata
- Authors
- Japanese Society for Cancer of the Colon and Rectum, Watanabe, T., Muro, K., Ajioka, Y., Hashiguchi, Y., Ito, Y., Saito, Y., Hamaguchi, T., Ishida, H., Ishiguro, M., Ishihara, S., Kanemitsu, Y., Kawano, H., Kinugasa, Y., Kokudo, N., Murofushi, K., Nakajima, T., Oka, S., Sakai, Y., Tsuji, A., Uehara, K., Ueno, H., Yamazaki, K., Yoshida, M., Yoshino, T., Boku, N., Fujimori, T., Itabashi, M., Koinuma, N., Morita, T., Nishimura, G., Sakata, Y., Shimada, Y., Takahashi, K., Tanaka, S., Tsuruta, O., Yamaguchi, T., Yamaguchi, N., Tanaka, T., Kotake, K., & Sugihara, K.
- Affiliations
- The University of Tokyo (JP)
- Aichi Cancer Center (JP)
- Niigata University (JP)
- National Cancer Center Hospital (JP)
- Saitama Medical Center, Saitama Medical University (JP)
- Tokyo Medical and Dental University (JP)
- St Mary's Hospital (JP)
- Shizuoka Cancer Center (JP)
- The Cancer Institute Hospital (JP)
- St. Marianna University School of Medicine (JP)
- Kyoto University (JP)
- Kagawa University (JP)
- National Defense Medical College (JP)
- National Cancer Center Hospital East (JP)
- Shinko Hospital (JP)
- Tokyo Women's Medical University (JP)
- Aomori Prefectural Central Hospital (JP)
- Misawa City Hospital (JP)
- Tokyo Metropolitan Komagome Hospital (JP)
- Kurume University (JP)
- Seirei Sakura Citizen Hospital (JP)
- Tochigi Cancer Center (JP)
- Corresponding author
- Watanabe, Toshiaki
- ORCID
- Watanabe, Toshiaki
- Muro, Kei
- Ajioka, Yoichi
- Hashiguchi, Yojiro
- Saito, Yutaka
- Hamaguchi, Tetsuya
- Ishiguro, Megumi
- Ishihara, Soichiro
- Kanemitsu, Yukihide
- Kinugasa, Yusuke
- Murofushi, Keiko
- Nakajima, Takako
- Oka, Shiro
- Sakai, Yoshiharu
- Uehara, Keisuke
- Ueno, Hideki
- Yamazaki, Kentaro
- Yoshida, Masahiro
- Yoshino, Takayuki
- Boku, Narikazu
- Itabashi, Michio
- Morita, Takayuki
- Shimada, Yasuhiro
- Takahashi, Keiichi
- Tanaka, Shinji
- Tanaka, Toshiaki
- Kotake, Kenjiro
- Sugihara, Kenichi
- Venue
- International Journal of Clinical Oncology
- Published
- 2017-03-27
- Volume
- 23
- Issue
- 1
- Pages
- 1-34
- ISSN
- 1341-9625 (ISSN-L)
- 1437-7772
- PMC
- PMC5809573
- OpenAlex
- W1990423062
- Cited by
- 2,467
- References
- 285
- Citations by year
- 2026: 15 · 2025: 106 · 2024: 243 · 2023: 256 · 2022: 270 · 2021: 343 · 2020: 322 · 2019: 234 · 2018: 144 · 2017: 116
- FWCI
- 98.39
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- International Journal of Clinical Oncology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Japan Society for the Promotion of Science (17K08691, 15K10150, 17K10655)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
- Keywords
- colorectal cancer, treatment guidelines, clinical practice variation, informed consent, classification of evidence, clinical questions, health insurance system, Japan
- MeSH terms
- Antineoplastic Combined Chemotherapy Protocols, Colonic Neoplasms, Humans, Japan, Liver Neoplasms, Lymph Node Excision, Laparoscopy, Rectal Neoplasms, Colorectal Neoplasms, Chemotherapy, Adjuvant, Dose Fractionation, Radiation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.